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Abstract
Background: Giant cell arteritis (GCA) is a common large vessel vasculitis of the elderly, often associated with sight
loss. Glucocorticoids (GC remain the mainstay of treatment, although biologic treatments have been approved.
Biomarkers predicting disease severity, relapse rates and damage are lacking in GCA.
EULAR recommends ultrasound (US) as the first investigation for suspected GCA. The cardinal US finding, a non-compressible
halo, is currently categorised as either negative or positive. However, the extent and severity of this finding may vary.
In this study, we hypothesise whether the extent and severity of the halo sign [calculated as a single composite Halo score
(HS)] of temporal and axillary arteries may be of diagnostic, prognostic and monitoring importance; whether baseline HS is
linked to disease outcomes, relapses and damage; whether HS can stratify GCA patients for individual treatment needs;
whether HS can function as an objective monitoring tool during follow up.
Methods: This is a prospective, observational study. Suspected GCA Participants will be selected from the GCA FTC at the
participating centres in the UK. Informed consent will be obtained, and patients managed as part of standard care. Patients
with GCA will have HS (temporal and axillary arteries) measured at baseline and months 1,3,6 and 12 long with routine clinical
assessments, blood sampling and patient-reported outcomes (EQ5D). Non-GCA patients will be discharged back to the referral
team and will have a telephone interview in 6months.
We aim to recruit 272 suspected GCA referrals which should yield 68 patients (25% of referrals) with confirmed GCA. The
recruitment will be completed in 1 year with an estimated total study period of 24months.
Discussion: The identification of prognostic factors in GCA is both timely and needed. A prognostic marker, such as the HS,
could help to stratify GCA patients for an appropriate treatment regimen. Tocilizumab, an IL-6R blocking agent, switches off
the acute phase response (C-Reactive Protein), making it difficult to measure the disease activity. Therefore, an independent
HS, and changes in that score during treatment and follow-up, maybe a more objective measure of response compare to
patient-reported symptoms and clinical assessment alone.
Keywords: Outcomes in GCA, Risk stratification, Prognostic factors, Halo score, GCA probability score, Clinical severity index,
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Background
Giant cell arteritis (GCA) is a common form of systemic
vasculitis characterised by granulomatous inflammation of
large and medium-sized arteries [1]. GCA predominantly
affects Caucasian, older people (> 50 years), with a peak
incidence among those 70–80 years old [1, 2]. The inci-
dence of GCA rises with increasing age, ranging from 2.6
per 100,000 in patients aged 50–59 to 44.6 per 100,000 in
patients over the age of 80 [3]. GCA predominantly in-
volves branches of the external carotid arteries such as the
temporal arteries and the aorta and its large branches,
including the subclavian and axillary arteries. Common
presenting symptoms include new headache, scalp tender-
ness, jaw claudication, diplopia and amaurosis fugax [1, 2,
4]. GCA can cause significant morbidity and ischaemic
complications, including irreversible sight loss. Other
complications include aortitis, myocardial infarction and
stroke. The 1990 American College of Rheumatology
(ACR) classification criteria were not intended for diagno-
sis [5] and may not be accurate, particularly for cases with
ophthalmic involvement [6]. The criteria have low specifi-
city and predictive values [2, 7, 8]. Screening tests are vital
as the GCA symptoms can be often non-specific and miss-
ing the diagnosis can be devastating [9].
Glucocorticoids (GC) have remained the cornerstone
of treatment for GCA [10], although cohort studies show
only 15–20% sustained remission with glucocorticoids
alone Glucocorticoid-sparing treatments in GCA are
also needed due to the harmful effects of long-term
glucocorticoid use. This includes hypertension, hypergly-
caemia, osteoporosis, cushingoid changes, mood disturb-
ance and electrolyte imbalance, but this is not an
exhaustive list [11, 12]. It is recommended to start GC
immediately in strongly suspected GCA pending in-
vestigations [13]. Targeted treatments have recently
been introduced, but heterogeneity in disease out-
comes has still been observed. In GiACTA, the land-
mark trial of Tocilizumab in GCA that provides the
evidence base for its current use, 42% of participants
randomised to weekly Tocilizumab still did not
achieve sustained remission [14]. Currently, validated
biomarkers predicting disease severity, relapse rates
and damage are lacking in GCA.
A positive temporal artery biopsy (TAB) has been the
gold standard for histological diagnosis of GCA [15–17].
However, a biopsy is invasive, and it lacks sensitivity.
This is particularly true in extra-cranial involvement,
termed large-vessel GCA (LV-GCA), where access to
sample material has obvious practical constraints and is
usually identified incidentally following cardiovascular
surgery [18]. Non-invasive imaging techniques, including
ultrasound (US), Magnetic resonant image (MRI) and
position emission tomography (PET-CT) are increasingly
being used to identify these patients [19–21].
Ample evidence now indicates that US of temporal ar-
teries can promptly diagnose cranial forms of GCA, as
well as screening for LV-GCA at the axillary arteries
[22]. US is a safe, non-invasive and higher sensitivity,
particularly in extra-cranial disease. It is a relatively
quick procedure [23], often delivered as a point of care
test, well tolerated by patients and is suitable for follow-
up examinations. Timely diagnosis of GCA by ultra-
sound in GCA fast track clinics has resulted in a signifi-
cant reduction in permanent visual loss [24–26].
The EULAR recommendations for imaging in Large
Vessel Vasculitis recommend US of temporal and/or ax-
illary arteries as the first imaging modality, where there
is adequate expertise and equipment, particularly in pa-
tients with suspected predominantly cranial GCA [27].
Estimation of GCA probability has become important
given recent EULAR recommendations suggesting differ-
ent diagnostic strategies in patients with low, intermedi-
ate or high GCA probability. In patients where there is a
high clinical suspicion of GCA and an initial positive im-
aging test e.g. US, the diagnosis of GCA may be made
without additional investigations (e.g. biopsy or further
imaging). In patients with a low clinical probability and a
negative imaging result, the diagnosis of GCA can be con-
sidered unlikely, and the patient reassured [18]. There is
also a report from Southend suggesting that the ‘pre-test
GCA Probability Score’ may be a useful tool for rating the
pre-test probability of GCA, stratifying patients into ‘low’
or ‘not-low’ probability groups [28]. This score may also
reflect clinical severity and extent of disease.
The main finding on US in GCA patients is the halo sign:
non-compressible hypoechoic wall swelling [29, 30]. Several
studies have been conducted to investigate the accuracy,
construct and criterion validity of US in the diagnosis of
GCA [31–34]. The latest meta-analysis of prospective stud-
ies has shown a pooled sensitivity of 77% and a pooled spe-
cificity of 96% for temporal artery US when compared to
the final clinical diagnosis of GCA [35]. US allows measure-
ment of the arterial intimal media complex (IMC). Studies
show that at the age of 70 years the temporal artery has a
normal IMC diameter of about 0.2mm, whilst inflamed
temporal arteries have a diameter of 0.5–0.9mm [27, 36].
Axillary arteries of patients aged about 70 have a normal
IMC diameter of 0.6mm, whilst patients with extra-cranial
GCA have an average diameter of 1.6–1.7mm [36, 37]. A
cut off value was determined at 1.0mm [36]. Currently, the
temporal artery US of GCA patients are categorised as ei-
ther negative or positive. However, variation in extent and
severity of these findings on temporal and axillary artery
US in GCA is observed [38]. We have recently developed
an ultrasonographic halo score that correlates with arterial
inflammation in GCA [39]. In the current study, will further
investigate the novel halo score as a diagnostic, prognostic
and disease monitoring tool for GCA.
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We will systematically measure the extent and severity
of the halo sign. Bilateral US assessment of the common
temporal artery, the parietal branch, the frontal branch
and axillary arteries will be performed (Figs. 1 and 2).
The halo sign at each branch of the common temporal,
parietal and frontal arteries will be scored 0–4 points,
giving a maximum possible halo score (HS) score of 24
(Table 1). At the axillary arteries, the IMT will be scored
0–4 points on each side, allowing a maximum total score
8, which will be multiplied by 3 (Fig. 2). A total halo
score (THS) will be constructed by adding the scores of
the temporal artery branches with the axillary artery score.
Subsequently, the HS and THS will be assessed for any
correlation to disease outcomes in GCA, as characterised
Fig. 1 Diagram demonstrating the six temporal artery segments for calculating the temporal artery halo score
Fig. 2 Diagram demonstrating the six temporal artery segments and two axillary arteries for calculating the total artery halo score
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by responsiveness to therapy - remitting, relapsing or re-
fractory disease. Other outcome measures that may be
reviewed include the development of large vessel disease
and vascular damage (as assessed by cross-sectional scan-
ning such as PET-CT), accumulation of glucocorticoid re-
lated adverse events and need for additional conventional
(e.g. leflunomide, methotrexate) or biologic (Tocilizumab)
DMARDs. Remitting disease in GCA is defined as a disease
under sustained satisfactory control with minimum one
flare during standard GC taper. The relapsing disease is
where the condition initially comes under control but then
flares on GC tapering. Refractory GCA patients are those
who do not respond to GC at all.
The identification of prognostic factors in GCA is both
timely and needed. The GiACTA trial has shown that
IL-6R blocking therapy may help to sustain glucocortic-
oid free remission [14]. In addition, the GiACTA trial
has shown that a subset of GCA patients can be quickly
withdrawn from glucocorticoid therapy without the devel-
opment of relapses. A prognostic marker, as outlined
above, could help to stratify GCA patients to an appropri-
ate treatment regime. IL-6R blockade switches off the in-
flammatory marker response, making it difficult to use
traditional biomarkers such as CRP to measure disease ac-
tivity. Therefore, an independent HS, and changes in that
score during treatment and follow-up, maybe a more ob-
jective measure of response, rather than relying only on
patient-reported symptoms and clinical assessment.
Methods/design
Study aims and hypothesis
To determine whether the severity of vessel wall oedema
(halo/IMT) in the common temporal artery, its branches
and the axillary arteries, as measured by a composite
ultrasound score (THS), is of prognostic value in pre-
dicting severity and outcomes in GCA.
To determine the prognostic and monitoring value of
the HS and THS in GCA, with regards to predicting out-
comes (remission, refractory or relapsing disease) in
GCA. We will also determine the diagnostic value of the
HS and THS for discriminating GCA from non- GCA.
Study design
This is a pragmatic, prospective, observational study.
This study will involve two specific phases
1) Initial presentation and diagnosis of GCA or non-GCA.
2) Follow-up over 12 months for GCA patients and 6
months for non-GCA patients.
Initial presentation and diagnosis
This phase will involve recruiting patients from the
GCA FTP at participating sites. Patients recruited will
be subject to inclusion/exclusion criteria detailed
below. Their General Practitioner, Emergency Depart-
ment or other specialities refer patients to the FTP.
Patients will be invited to participate in this study by
the Rheumatology Research team, who will provide
them with information about the study. Patients will
be informed of the phases of participation, the volun-
tary nature of the study, and their right to withdraw
at any stage. Written consent to participate will be
obtained by the researcher prior to the commence-
ment of the screening assessments.
In this phase following will be assessed: (Additional file 1)
 Clinical history
 Clinical examination
 Routine bloods including biomarkers
 Patient-reported outcome (EQ5D)
 Starting dose of GC
 US scan of the temporal artery including its
branches (frontal and parietal) and the axillary artery
bilaterally
 Probability score (Additional file 3) GCA Probability
score will be calculated on all the patients referred
to the FTP to clinically stratify their risk of having
GCA and as a measure of severity of the disease
A diagnosis of GCA will be based on revised classification
criteria as proposed recently (Dejaco et al. Rheumatology
2016) in the modified GiACTA criteria detailed below. The
accuracy of the diagnosis will be evaluated after 6months.
Patients were classified as having GCA if all of the
following criteria were met
 Age ≥ 50 years with ESR > 30mm/hr. or CRP > 10mg/L
 Unequivocal cranial symptoms of GCA (i.e. new-
onset localised headache, scalp or temporal artery
tenderness, ischemia-related vision loss, or otherwise
unexplained mouth or jaw pain upon mastication)
or symptoms of polymyalgia rheumatica (PMR), de-
fined as shoulder and/or hip girdle pain associated
with inflammatory morning stiffness
a. Cranial symptoms defined as new localised head
pain, generalised scalp tenderness, tender temporal
Table 1 Halo Score Grading
Halo
Grading
Common
superficial TA
halo thickness
(mm)
Parietal TA
halo thickness
(mm)
Frontal TA
halo thickness
(mm)
Axillary
artery halo
thickness
(mm)
Grade 0 0.3 or less 0.2 or less 0.1 or less 0.5 or less
Grade 1 0.4 0.3 0.2 0.6
Grade 2 0.5 0.4 0.3 0.7–0.8
Grade 3 0.6–0.7 0.5* 0.4 0.9–1.5
Grade 4 0.8 or more 0.6 or more 0.5 or more 1.6 or more
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artery, AION or PION, jaw claudication or tongue
claudication in the current study
b. PMR symptoms defined as morning stiffness > 1 h
with bilateral shoulder pain and/or bilateral hip
pain or stiffness in the current study
 Temporal artery biopsy revealing features of GCA or
evidence of GCA by imaging (i.e. ultrasound or
cross-sectional imaging such as CTA or PET-CT)
Follow-up period: (Additional file 1)
Participants who are diagnosed with GCA will be seen for
follow-up visits at 1, 3, 6 and 12months. Participants with
a non-GCA diagnosis will be seen or through a telephone
interview one further time at 6months to confirm the
non-GCA diagnosis. At any time, point throughout the
follow-up period patients may require unscheduled visits if
they have symptoms of relapse. Patients will be educated at
baseline as to the symptoms that might be expected with
relapse and guided to contact their clinician or Rheumatol-
ogy Research team (if different) immediately (Fig. 3).
For study purposes, relapse means those patients
whose GCA symptoms flare or return in response to
current standard treatment, that is a tapering regimen of
glucocorticoids. Refractory GCA patients are those who
do not respond from the outset.
In this phase, following will be assessed:
 Clinical history
 Clinical examination
 Routine bloods including biomarkers
 US scan of the temporal artery including its branches
(frontal and parietal) and the axillary artery bilaterally
 Patient-reported outcomes (EQ5D)
 Cumulative GC requirement
DEFINITION OF RELAPSE AND REMISSION
1. Remission is defined as absence of clinical signs and symptoms of
GCA and normalization of ESR [< 30 mm/hr] and CRP [< 10 mg/L]
2. Relapse is defined as recurrence of symptoms attributable to
active GCA, with or without ESR > 30 mm/hr. and CRP > 10 mg/L
3. The refractory non-remitting disease subjects are those who
have had no remission within 6 weeks of initiation of high dose
glucocorticoid treatment.
Eligibility criteria
Patients with clinical suspicion of GCA referred to the
FTC would be eligible for the study subjects to the
inclusion and exclusion criteria below.
Fig. 3 Study Flow chart
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Inclusion criteria
The clinician responsible for the patient’s care will make
the diagnosis of GCA as part of the standard of care
using the modified GiACTA criteria.
 Age ≥ 50 years with ESR > 30mm/hr. or CRP > 10mg/L
 Unequivocal cranial symptoms of GCA (i.e. new-
onset localised headache, scalp or temporal artery
tenderness, ischemia-related vision loss, or otherwise
unexplained mouth or jaw pain upon mastication)
or symptoms of polymyalgia rheumatica (PMR), de-
fined as shoulder and/or hip girdle pain associated
with inflammatory morning stiffness
a. Cranial symptoms defined as new localised head
pain, generalised scalp tenderness, tender
temporal artery, AION or PION, jaw claudication
or tongue claudication in current study
b. PMR symptoms defined as morning stiffness > 1
h with bilateral shoulder pain and/or bilateral
hip pain or stiffness in the current study
 •Temporal artery biopsy revealing features of GCA
or evidence of GCA by imaging (i.e. ultrasound or
cross-sectional imaging such as CTA or PET-CT)
 •Participants must have the capacity and willingness
to give informed written consent
Exclusion criteria
 Participants must not have a previous diagnosis of
GCA
 Participants must not have had a previous temporal
artery biopsy i.e. as part of diagnostics for previously
suspected GCA
 Participants must not be under 18 years
 Participants must not be on treatment with a high
dose of steroids (> 7.5 mg) more than 2 weeks prior
to the first review in the FTP
 Inability to give informed consent
Sampling
The nature of this disease is rare; thus, the number of
participants will be collected up to 12 months and will
be followed up to 12 months as per the study protocol.
Patients will be recruited after referral to the
participating site FTP.
Participants The cohort of patients for this study will be
recruited from the fast track GCA clinics (FTC), which is
currently the standard of care for patients with clinical
suspicion of GCA. The FTC has been demonstrated a
reduced incidence of vision loss and cost-effectiveness [8].
Patients can be referred to the FTC from General Practi-
tioners (GP), Emergency Department (ED), Ophthalmol-
ogy or from any other specialities. Initial assessment
includes clinical assessment (patient history and physical
examination), blood tests (ESR, CRP, full blood count,
renal profile, liver function tests), and US of the Temporal
and axillary arteries. Those who are diagnosed with GCA
will be monitored in the GCA follow-up clinics. Those pa-
tients with low probability and a non-GCA diagnosis
would be referred back to the primary referral team.
Intervention
Potential study participants will be identified from
patients referred by their GP, ED, Ophthalmology or other
specialities to the FTP. For study purposes, referred
patients will be informed about the study and provided
with a study invitation letter and patient information
sheet (PIS) during the first contact with the research team.
All participants will need to provide written, informed
consent to take part in the study. Due to the nature of the
study, researchers will provide as much as information as
possible at the time of the first assessment. The research
team will answer any questions from the patients. Patients
are reassured that their decision will not impact on their
standard of care. Those who understand and agreed to
participate will be consented and given a unique
identification number.
The US of the temporal artery branches and axillary
artery on both sides is a key element of the study, which
will measure the IMT of each artery and a total halo
score (THS) calculated. This score will be used to assess
the severity of the disease. It will also be calculated on
each follow-up visit to determine how the THS changes
with treatment.
Operator’s experience
 All sonographers participating in this study have
experience of scanning more than 30 people with
temporal artery and axillary scans and at least 5
cases with GCA.
 All sonographers have completed either face to face
or web-based training on the temporal artery and
axillary artery scanning requirements for this study.
 All sonographers have completed the online BSR e-
learning module on Ultrasound scanning for LVV
 We have documented the experience of
sonographers and equipment characteristics with
completion of a standardised form (Additional file 4)
Outcome measures
Primary outcome
1. Analysis of data to see how many patients had
sustained remission (achieving a daily prednisolone
dose of ≤5 mg of glucocorticoid dose equivalent) at
12 months from baseline (one flare is acceptable in
Sebastian et al. BMC Rheumatology            (2020) 4:35 Page 6 of 10
this study period). All patients follow the same
tapering scheme as outlined in the British Society
for Rheumatology (BSR) guidelines (Additional file
2). To then determine if the initial baseline HS
correlates with this clinical outcome at 12 months.
Secondary outcomes
1. To determine if a change in HS over the 12-month
disease monitoring period correlates to prognosis
2. To determine if there is any correlation of HS to
quality of life measures, as assessed by EQ5D
3. To determine any correlation between the HS and
biomarkers of GCA patients
4. Evaluate if the Probability Score (Additional file 3)
prospectively correlates with GCA outcomes at 12
months
5. To determine the diagnostic accuracy of the HS for
discriminating GCA from non-GCA Reference
standard for the diagnosis of GCA will be the clin-
ical diagnosis after 6 months follow-up.
6. To determine the diagnostic accuracy of the GCA
probability score for discriminating GCA from non-
GCA patients. The reference standard for the diag-
nosis of GCA will be the clinical diagnosis after 6
months follow-up.
Data analysis and monitoring
Descriptive statistics such as mean (with standard
deviation), median (with range) and percentages will be
used for reporting HS, relative change in HS, number of
patients in remission with prednisolone dose ≤5 mg daily
after 12 months, cumulative prednisolone dose at 12
months follow-up, time to first relapse, number of re-
lapses, levels of inflammatory markers, quality of life
questionnaire outcomes and GCA probability scores.
Temporal artery, axillary artery halo scores and the total
halo score (temporal score plus axillary score) will be
calculated.
Primary outcome analysis and power calculation
Percentages of GCA patients in remission with a
prednisolone dose of ≤5 mg per day will be determined
at 12 months follow-up. A ROC analysis of baseline HS
will be performed to identify the optimal HS cut-off
point that discriminates between patients reaching re-
mission and those that do not. Subsequently, the Chi-
square test will be used to compare remission rates at
12 months follow-up between patients with a HS above
the optimal cut-off point versus those with a HS below
the optimal cut-off points.
A power calculation was performed to determine the
number of patients needed for investigating this primary
outcome. Based on two previous studies, it is expected
that 45% of GCA patients will be in remission at 12
months with a prednisolone dose of ≤5mg per day [40,
41]. For the current study, we propose that a 40%
difference in patients reaching sustained remission at 12
months follow-up is clinically relevant.
As the optimal prognostic HS cut-off point is not yet
known, we propose that a 25% versus 75% distribution is
still clinically relevant. If the smallest group becomes
smaller (and the biggest group bigger), we believe risk
stratification by HS would have limited overall value for
clinical practice. With an alpha of 0.05 and power of
0.80, we calculate that 61 GCA patients are needed for
the study.
Taken into consideration a 10% loss of patients during
12months follow-up, we expect that 68 GCA patients
should be initially recruited into the study.
In our experience, 25% of patients entering a GCA
FTP, will be ultimately diagnosed with GCA after 6
months follow-up. Thus, we anticipate that we would
need to recruit a total of 272 patients suspected of hav-
ing GCA in our study, of which 68 are eventually diag-
nosed as having GCA.
G.Power 3.1.9.4
z tests Proportions: Difference between two independent
proportions
Analysis A priori: Compute required sample size
Input Tail(s) = Two
Proportion p2 = 0.65
Proportion p1 = 0.25
α err prob = 0.05
Power (1-β err prob) = 0.80
Allocation ratio N2/N1 = 3
Output Critical z = 1.9599640
Sample size group 1 = 15
Sample size group 2 = 46
Total sample size = 61
Actual power = 0.7979079
Secondary outcome analysis
 In patients with a clinical diagnosis of GCA: the
prognostic value of the absolute and relative change
in HS between baseline and 1 month’s follow-up will
be investigated in a similar analysis as mentioned
under the primary outcome analysis
 In patients with a clinical diagnosis of GCA: we will
perform a paired analysis of the HS measured at
different time points by paired t-test or Wilcoxon
signed-rank rest depending on normality of the data
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 In patients with a clinical diagnosis of GCA:
correlation between HS and measures of quality of life
will be determined by Pearson or Spearman’s rank
correlation coefficient depending on normality of data
 In patients with a clinical diagnosis of GCA:
correlation between HS and inflammatory markers
in blood will be determined by Pearson or
Spearman’s rank correlation coefficient depending
on normality of data
 In patients with a clinical diagnosis of GCA: the
prognostic value of the GCA probability score will
be assessed similar to the analysis of the prognostic
value of the HS as mentioned under the primary
outcome analysis
 In all patients suspected of having GCA: the
diagnostic accuracy of the HS for discriminating
GCA from non-GCA patients will be determined by
ROC analysis and the Youden index. Sensitivity, spe-
cificity and likelihood ratios at the optimal diagnos-
tic cut-off point will be evaluated. The reference
standard for the diagnosis of GCA will be the clin-
ical diagnosis after 6 months follow-up.
 In patients with a clinical diagnosis of GCA: the
diagnostic accuracy of the HS for discriminating
relapsing and non-relapsing GCA patients during
follow-up measurements. Sensitivity, specificity and
likelihood ratios at the optimal diagnostic cut-off
point will be evaluated. Relapse definition is de-
scribed elsewhere.
 In patients with a clinical diagnosis of GCA: the
predictive effect of the baseline HS and GCA
probability score on GCA patients achieving
remission at 12 months with prednisolone dose of
≤5 mg will be evaluated by multivariate logistics
regression analysis.
 In patients with a clinical diagnosis of GCA: the
predictive effect of the HS and GCA probability
score on cumulative prednisolone dose at 12 months
follow-up will be evaluated by multivariate linear re-
gression analysis.
 In addition to the total halo score in the axillary and
temporal artery, changes in individual vessel halo
grades will be analysed.
Discussion
US is a non-invasive procedure, safe and easily accessible
and repeatable in the clinic setting, without any radiation
exposure to the patient or the sonographer. EULAR rec-
ommends US as a first choice imaging investigation in
suspected GCA [27], and BSR strongly recommends US
or TAB as a confirmatory test in suspected GCA [13]. A
recent study Monti et al. suggests the use of US as a sur-
rogate tool to replace TAB [42]. US has now become an
essential part of the workup of GCA in many centres.
However, current US practice in GCA is to declare the
test either positive or negative for the ‘Halo sign’ in a di-
chotomous manner. The extent and severity of the halo
sign in assessing disease diagnosis (in the context of dif-
fering pre-test probabilities), severity and prognosis is
yet to be studied.
Halo is a dark hypoechoic area around the vessel lumen
representing the vessel wall inflammation. In temporal
arteries, halo compression sign, with a video in the
transverse plane will be assessed to confirm all diagnoses of
GCA. Non-compressible halo is the key lesion in GCA.
Halo thickness will be measured in TA, its branches and
axillary arteries. We will be using the published cut off
values of the IMT of TA as assessed by the high-frequency
probe (22MHz) [37]. We will use the 18MHz probe in this
study which is compliant with EULAR recommendations
of using a probe of frequency > 15MHz. We recently devel-
oped a halo score grading the halo thickness in temporal
and axillary arteries [39]. Ultrasound halo score correlates
with the vascular inflammation in GCA and strongly associ-
ated with ocular ischemia in GCA [39].
Although, the US is a useful tool to study the
haemodynamic and morphology of the blood vessels [43]
it remains a challenge to interpret of the morphological
changes in the different size of the blood vessels. A follow-
up study observed an 85% reduction of the vessel wall in
temporal artery with treatment contrasted to the large
vessels showing a reduction of 45% [44]. A possible ex-
planation for this is the inclusion of popliteal and femoral
arteries which are frequently involved by atherosclerosis.
Our current study may have a potential solution to this as
it will validate the cut off scores for each temporal artery
branch and the axillary arteries and sum these changes by
measuring the total halo score.
The identification of prognostic factors in GCA is both
timely and needed. Recent BSR guidelines recommend
initiating high dose of GC immediately in highly suspected
patients with GCA [13]. At presentation, extensive vascular
involvement of both cranial and large vessels evidenced by
US showed a poor response to GC treatment in GCA and
often required steroid-sparing agents [45]. A case series
showed a significant vessel wall reduction evidenced in US
and PET CT in response to Tocilizumab treatment in large
vessel GCA [46]. The GiACTA trial has shown that IL-6R
blocking therapy may help to sustain glucocorticoid free re-
mission. A prognostic marker, such as the HS, could help
to stratify GCA patients for an appropriate treatment regi-
men. IL-6R blockade switches off the inflammatory marker
response, making it difficult to use traditional biomarkers
such as CRP to measure disease activity. Therefore, an in-
dependent HS, and changes in that score during treatment
and follow-up, may be a more objective measure of re-
sponse, rather than relying only on patient reported symp-
toms, clinical assessment and acute phase markers (CRP).
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